(Q35173065)

6 August 2017

1 reference

title

Therapeutic approaches to bladder cancer: identifying targets and mechanisms (English)

1 reference

6 August 2017

1 reference

Richard J Cote

1

1 reference

PubMed ID

12850529

6 August 2017

Ram H Datar

series ordinal

2

1 reference

PubMed ID

12850529

6 August 2017

language of work or name

1 reference

1 June 2003

1 reference

Critical Reviews in Oncology Hematology

6 August 2017

1 reference

6 August 2017

46 Suppl

1 reference

6 August 2017

S67-83

1 reference

Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Neo-adjuvant chemotherapy in invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Immunotherapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

An overview of intravesical therapy for superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

The treated natural history of high risk superficial bladder cancer: 15-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year followup

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Neoadjuvant chemotherapy for invasive bladder carcinoma: disease outcome and bladder preservation and relationship to local tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Pharmacotherapy of bladder cancer--practice and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Second-line chemotherapy in advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

New drugs and new approaches for the treatment of metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Apoptosis. Its significance in cancer and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Accumulation of nuclear p53 and tumor progression in bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Genes for human arylamine N-acetyltransferases in relation to loss of the short arm of chromosome 8 in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

p53 is required for radiation-induced apoptosis in mouse thymocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

p53 status and the efficacy of cancer therapy in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

p53 and treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Clinical significance of thymidylate synthase expression in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Apoptosis-targeted therapies for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Apoptosis in cancer therapy: crossing the threshold

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Apoptosis: a link between cancer genetics and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Genetic analysis of chemoresistance in primary murine lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

The Bcl2 family: regulators of the cellular life-or-death switch

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

From bench to clinic with apoptosis-based therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

The contributions of cyclooxygenase-2 to tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

NF-kappaB at the crossroads of life and death

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Effects of NFkappaB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Angiogenic factors and bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with Cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Cantilever-based optical deflection assay for discrimination of DNA single-nucleotide mismatches

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Intravesical therapy in superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Origin of nanomechanical cantilever motion generated from biomolecular interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

A novel tumor-specific gene therapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Human urinary bladder carcinomas express adenovirus attachment and internalization receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Gene therapy for bladder cancer using adenoviral vector

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Epidermal growth factor receptor-targeted therapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Anti-epidermal growth factor receptor drugs in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

The EGFR as a target for anticancer therapy--focus on cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

ZD1839 (Iressa): what's in it for the patient?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Camptothecins: a review of their chemotherapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Angiogenesis inhibitors in the treatment of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

Proteomics in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900066-0

7 January 2021

10.1016/S1040-8428(03)00066-0

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12850529